Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences (ARTL) entered into a private placement on 1 Aug 2025, selling 593,252 common shares at $10.20 and 313,435 prefunded warrants at $0.001, each paired with one three-year warrant at $10.20 and one at $50.00. Unit prices of $10.45 (shares) or $10.449 (prefunded) will deliver $9.475 million in gross cash; full cash exercise of the 1.81 million bundled warrants could raise an additional $64.1 million.
Proceeds from the share sale will be used immediately to purchase the cryptocurrency Solana (SOL). Any warrant cash will first fund 12 months of operating requirements; remaining amounts may also be deployed into SOL. The shift establishes a new cryptocurrency treasury strategy and triggers extensive risk disclosures covering SOL price volatility, regulatory uncertainty, Nasdaq listing compliance, Investment Company Act exposure and potential CAMT liabilities.
The offering, exempt under Reg D, is expected to close 5 Aug 2025, with a resale registration due within 15 days. In a separate 7.01 disclosure, the company announced favourable UK MHRA guidance for a first-in-human Phase 1 trial of anxiety-depression candidate ART12.11.
Artelo Biosciences, Inc. (ARTL) filed a new Form D on 9 Jul 2025 that covers a $1.425 million private placement conducted under Regulation D Rule 506(b).
- Total offering & amount sold: $1,425,000; amount remaining: $0, indicating the raise is already fully subscribed.
- Date of first sale: 26 Jun 2025; the company does not expect the offering to last longer than one year.
- Securities offered: common equity, options/warrants, and the shares issuable upon exercise of those instruments.
- Investors: 8 accredited investors participated; no non-accredited investors and no minimum investment requirement were specified.
- Costs: No sales commissions or finders’ fees were paid, and none of the proceeds are earmarked for payments to directors, officers, or promoters.
- Industry & issuer details: Nevada-incorporated biotechnology company; revenue size not disclosed.
The notice signals completion of a small but cost-efficient capital raise that adds liquidity while increasing potential share count through equity-linked securities.
Artelo Biosciences (Nasdaq: ARTL) entered into a securities purchase agreement on 24-Jun-2025 for a private placement of 136,843 common shares at $5.82 plus warrants covering 783,249 shares.
Gross proceeds: $1.425 million today, up to $6.403 million if all warrants are exercised. Instruments include pre-funded warrants (93,180 shares, $0.001 strike) and 5-year warrants at $5.82 (460,046 shares) and $10.00 (230,023 shares), all subject to 4.99%-9.99% ownership caps.
- Unit price: $6.195 per share and three warrants.
- Closing expected 26-Jun-2025.
- Company will file resale registration within 15 days.
- $250,000 of net proceeds earmarked to purchase SOL cryptocurrency; remainder for working capital.
The sale is exempt under Rule 506 of Regulation D; investors are accredited.